Novartis: more than 25 potential blockbusters, group says
(CercleFinance.com) - Novartis' pipeline includes more than 25 potential blockbuster drugs, with the Swiss drugmaker mostly betting on oncology, it said on Thursday.
At the group's management day today at its research headquarters in Cambridge (United States), Novartis said its oncology division - which returned to growth in 2018 - is now "well positioned".
The oncology business has a portfolio including seven in-market blockbusters, and recently launched three drugs with "blockbuster potential," it said.
Novartis said it has several pipeline milestones this year, including six major readouts that could potentially accelerate the group's growth momentum.
These steps include the heart drug Entresto and the asthma drug Fevipiprant, while in oncology the first combination with Novartis PD1 spartalizumab.
Novartis also said that it expects double-digit growth in China, and the stock was up 0.2% today in Zurich.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
At the group's management day today at its research headquarters in Cambridge (United States), Novartis said its oncology division - which returned to growth in 2018 - is now "well positioned".
The oncology business has a portfolio including seven in-market blockbusters, and recently launched three drugs with "blockbuster potential," it said.
Novartis said it has several pipeline milestones this year, including six major readouts that could potentially accelerate the group's growth momentum.
These steps include the heart drug Entresto and the asthma drug Fevipiprant, while in oncology the first combination with Novartis PD1 spartalizumab.
Novartis also said that it expects double-digit growth in China, and the stock was up 0.2% today in Zurich.
Copyright (c) 2019 CercleFinance.com. All rights reserved.